Argon laser photocoagulation for idiopathic neovascularization. Results of a randomized clinical trial
- PMID: 6193772
- DOI: 10.1001/archopht.1983.01040020360003
Argon laser photocoagulation for idiopathic neovascularization. Results of a randomized clinical trial
Abstract
The Idiopathic Neovascularization Study is a multicenter controlled clinical trial designed to determine whether argon laser photocoagulation is useful in preventing severe visual loss in eyes with a choroidal neovascular membrane (NVM) and no other clinically significant eye disease. Patients with an NVM 200 to 2,500 microns from the center of the foveal avascular zone were randomly assigned to argon laser photocoagulation (n = 33) or to observation (n = 34) groups. While the sample size of 67 eyes is insufficient to yield independent, definitive results, the pattern of treatment benefit is similar to that observed in two other controlled trials of argon laser photocoagulation of NVMs, the Senile Macular Degeneration Study and the Ocular Histoplasmosis Study. It is reasonable to conclude that patients with idiopathic NVMs, treated according to study protocol, may derive a similar benefit.
Similar articles
-
Argon laser photocoagulation for ocular histoplasmosis. Results of a randomized clinical trial.Arch Ophthalmol. 1983 Sep;101(9):1347-57. doi: 10.1001/archopht.1983.01040020349002. Arch Ophthalmol. 1983. PMID: 6193771 Clinical Trial.
-
Krypton laser photocoagulation for idiopathic neovascular lesions. Results of a randomized clinical trial. Macular Photocoagulation Study Group.Arch Ophthalmol. 1990 Jun;108(6):832-7. Arch Ophthalmol. 1990. PMID: 1693498 Clinical Trial.
-
The influence of treatment extent on the visual acuity of eyes treated with Krypton laser for juxtafoveal choroidal neovascularization. Macular Photocoagulation Study Group.Arch Ophthalmol. 1995 Feb;113(2):190-4. doi: 10.1001/archopht.1995.01100020074032. Arch Ophthalmol. 1995. PMID: 7532395 Clinical Trial.
-
Current management of choroidal neovascularization.Ann Ophthalmol. 1988 Nov;20(11):415-20, 423. Ann Ophthalmol. 1988. PMID: 2466432 Review.
-
Observations following laser treatment for choroidal neovascularization.Arch Ophthalmol. 1988 Nov;106(11):1524-5. doi: 10.1001/archopht.1988.01060140692035. Arch Ophthalmol. 1988. PMID: 2461189 Review. No abstract available.
Cited by
-
Pegaptanib for myopic choroidal neovascularization in a young patient.Graefes Arch Clin Exp Ophthalmol. 2007 Jun;245(6):903-5. doi: 10.1007/s00417-006-0472-6. Epub 2006 Nov 18. Graefes Arch Clin Exp Ophthalmol. 2007. PMID: 17115175
-
Risk factors for choroidal neovascularization in young patients: a case-control study.Doc Ophthalmol. 1995-1996;91(3):207-22. doi: 10.1007/BF01204172. Doc Ophthalmol. 1995. PMID: 8886585
-
Effects of VEGF levels on anti-VEGF therapy for patients with idiopathic choroidal neovascularization.Mol Cell Biochem. 2018 Apr;441(1-2):173-179. doi: 10.1007/s11010-017-3183-x. Epub 2017 Sep 7. Mol Cell Biochem. 2018. PMID: 28884436 Clinical Trial.
-
Surgical removal vs observation for subfoveal choroidal neovascularization, either associated with the ocular histoplasmosis syndrome or idiopathic: I. Ophthalmic findings from a randomized clinical trial: Submacular Surgery Trials (SST) Group H Trial: SST Report No. 9.Arch Ophthalmol. 2004 Nov;122(11):1597-611. doi: 10.1001/archopht.122.11.1597. Arch Ophthalmol. 2004. PMID: 15534121 Free PMC article. Clinical Trial.
-
Surgical removal of idiopathic, myopic and age-related subfoveal neovascularization.Graefes Arch Clin Exp Ophthalmol. 1996 Aug;234 Suppl 1:S42-50. doi: 10.1007/BF02343047. Graefes Arch Clin Exp Ophthalmol. 1996. PMID: 8871149
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical